Observational Study to Assess Natural History in Cockayne Syndrome Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is an Observational Study of children under the age of 11 diagnosed with Cockayne Syndrome to assess the natural progression of Cockayne Syndrome disease, with special attention to hearing and physical changes in length or height, weight, head circumference, and arm span during standard treatment.
The primary analytical objective is to determine the rate of linear growth over a 6-month period in children < 2 years of age and over a 12-month period in children ≥ 2 years of age.
| Condition |
|---|
|
Cockayne Syndrome |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort |
| Official Title: | An Observational Study to Assess the Natural History Including Growth and Hearing in Patients With Cockayne Syndrome |
- The primary objective is to determine the rate of linear growth over a 6-month period in children < 2 years of age and over a 12-month period in children ≥ 2 years of age. [ Time Frame: 6 -12 months ] [ Designated as safety issue: No ]
- Hearing Test Results tabulated and with the severity/deficits to be correlated with patient age, height velocity, and Pediatric Evaluation of Disabilities Inventory (PEDI)Score [ Time Frame: 6-12 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
whole blood, plasma, serum, white blood cells, urine, tissue
| Estimated Enrollment: | 40 |
| Study Start Date: | September 2009 |
| Study Completion Date: | February 2011 |
| Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 1 Year to 11 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Pediatric patients up to 10 years of age for females and up to 11 years of age for males who have received a diagnosis of Cockayne Syndrome
Inclusion Criteria:
- Pediatric patients with a documented diagnosis of CS, as suggested by clinical features and possible confirmation by genetic consultation and analysis
Age of participation:
- At least 12 months of age at the time of signing Informed Consent/Assent
- Female patient's age will not be greater than 10 years of age at the time of signing Informed Consent/Assent
- Male patient's age will not be greater than 11 years of age at the time of signing Informed Consent/Assent
Exclusion Criteria:
- Severe contractures or physical deformities that in the opinion of the investigator would prevent accurate measurement of height, length and ulna length
- Patients that have taken growth hormone or growth hormone related medications within 12 months prior to the date of Informed Consent/Assent
- Known history of inborn error of hyperprolinemia (Type I or Type II)
Clinical features present at the time of initial screening that are associated with the terminal phases of the natural progression of CS suggesting safe travel and completion of the study and its assessments to be unlikely as judged by the Investigator, including any of the following:
- Continuous or intermittent dependence on supplemental oxygen at home during the prior six months
- Two or more hospitalizations for pneumonia during the prior 12 months;
- A documented net weight loss of at least 10%, which has not been recovered and which includes a significant net weight loss (beyond the estimated error of the measurement) over the most recent 6 months, despite intensive nutritional support including the use of gastrostomy tube feedings
- Presence of scoliosis with a Cobb's angle of 30º or greater
Contacts and Locations| United States, Massachusetts | |
| Harvard medical School, Children's Hospital Boston, Division of Genetics & Metabolism | |
| Boston, Massachusetts, United States, 02115 | |
| United States, New York | |
| New York University Medical Center | |
| New York, New York, United States, 10016 | |
| France | |
| Hopitaux Universitaires de Strasbourg, Service de Pédiatrie 1 | |
| Strasbourg, Cedex, France, 67098 | |
| United Kingdom | |
| St. Mary's Hospital, Genetic Medicine, 6th Floor, Oxford Road | |
| Manchester, United Kingdom, M13 9 WL | |
| Principal Investigator: | E. G. Neilan, MD, PhD | Children's Hospital Boston |
More Information
No publications provided
| Responsible Party: | Dr. E. Neilan, Principal Investigator, Children's Hospital Boston |
| ClinicalTrials.gov Identifier: | NCT00985413 History of Changes |
| Obsolete Identifiers: | NCT01230333 |
| Other Study ID Numbers: | MP1003-01 |
| Study First Received: | September 25, 2009 |
| Last Updated: | June 22, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by DNage B.V.:
|
Cockayne Syndrome pediatrics growth hearing Ageing |
Additional relevant MeSH terms:
|
Cockayne Syndrome Dwarfism Bone Diseases, Developmental Bone Diseases Musculoskeletal Diseases Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases |
Nervous System Diseases Abnormalities, Multiple Congenital Abnormalities Genetic Diseases, Inborn DNA Repair-Deficiency Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013